The CX3C Chemokine Receptor 1 pipeline drugs market research report outlays comprehensive information on the CX3C Chemokine Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the CX3C Chemokine Receptor 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Central Nervous System, Oncology, and Immunology which include the indications Myocardial Infarction, Atherosclerosis, Alzheimer’s Disease, Secondary Progressive Multiple Sclerosis (SPMS), Ovarian Cancer, Chronic Lymphocytic Leukemia (CLL), and Inflammation. It also reviews key players involved in CX3C Chemokine Receptor 1 targeted therapeutics development with respective active and dormant or discontinued products.
The CX3C Chemokine Receptor 1 pipeline targets constitutes close to nine molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 3, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
CX3C Chemokine Receptor 1 overview
CX3C Chemokine Receptor 1 is a receptor for the C-X3-C chemokine fractalkine (CX3CL1) present on many early leukocyte cells. CX3CR1-CX3CL1 signaling exerts distinct functions in different tissue compartments, such as immune response, inflammation, cell adhesion and chemotaxis. CX3CR1-CX3CL1 signaling also mediates cell migratory functions.
For a complete picture of CX3C Chemokine Receptor 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
